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The data for Problem 1 come from the Framingham Heart
Study, centered in Framingham, Massachusetts. Originat-
ing in 1948, the Framingham Heart Study is an ongoing
prospective study of risk factors for cardiovascular disease.
Two cohorts have been recruited into the Study and a
third cohort is currently being recruited. The Genetic Anal-
ysis Workshop 13 data set consists of genotyping informa-
tion from a 10-cM genome scan along with phenotypic
information on a number of phenotypes collected from
the first 21 examinations of the original cohort and the
first 5 examinations of the offspring cohort.
In 1948, the Framingham Heart Study-under the direction
of the National Heart Institute (now known as the
National Heart, Lung, and Blood Institute; NHLBI)-
embarked on an ambitious project in health research. At
the time, little was known about the underlying causes of
heart disease and stroke, but the death rates for cardiovas-
cular disease (CVD) had been increasing steadily since the
beginning of the 20th century and had become an Ameri-
can epidemic. Despite declines in the latter part of the cen-
tury, cardiovascular disease remains the top cause of death
in the US today.
The Framingham Heart Study is now conducted in collab-
oration with Boston University. Its objective is to identify
common factors or characteristics that contribute to CVD
by following its development over a long period of time
in a large group of participants who had not yet developed
overt symptoms of CVD or suffered a heart attack or stroke
[1]. The study was one of the first long-term prospective
studies and was planned for 20 years initially. It continues
today with more than 50 years of follow up on the origi-
nal cohort.
Framingham, Massachusetts was selected because it was a
moderate-sized town with a relatively stable population
that was thought to reflect many communities in the US
at that time. In the late 1940s it was estimated that about
10,000 individuals were in the age range 30–60 years in
this community and thus were eligible for recruitment to
a study of approximately 6000 subjects. The researchers
recruited 5209 subjects (2336 men and 2873 women)
between the ages of 28 and 62 from a systematic 2/3 sam-
ple of the households in the town of Framingham, Massa-
chusetts. The plan was to recruit all household members
in the age range of 30–60 years within each house that was
selected for study. Thus, the sample included 1644 spouse
pairs. Although there was no intention to recruit extended
families for family studies, many biologically related indi-
viduals were recruited, including siblings and some par-
ent-offspring pairs. Since 1948, members of the original
cohort have continued to return to the study every 2 years
from Genetic Analysis Workshop 13: Analysis of Longitudinal Family Data for Complex Diseases and Related Risk Factors
New Orleans Marriott Hotel, New Orleans, LA, USA, November 11–14, 2002
Published: 31 December 2003
BMC Genetics 2003, 4(Suppl 1):S2
<supplement> <title> <p>Genetic Analysis Workshop 13: Analysis of Longitudinal Family Data for Complex Diseases and Related Risk Factors</p> </title> <editor>Laura Almasy, Christopher I Amos, Joan E Bailey-Wilson, Rita M Cantor, Cashell E Jaquish, Maria Martinez, Rosalind J Neuman, Jane M  Olson, Lyle J Palmer, Stephen S Rich, M Anne Spence, Jean W MacCluer</editor> </supplement>
This article is available from: http://www.biomedcentral.com/1471-2156/4/s1/S2BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S2
Page 2 of 3
(page number not for citation purposes)
for a detailed medical history, physical examination, and
laboratory tests.
The study enrolled a second-generation-5124 of the origi-
nal participants' adult children and the spouses of these
adult children-to participate in similar examinations in
1971. Two thousand six hundred and sixteen of these sub-
jects are offspring of the spouse pairs from the original
cohort and 34 are stepchildren. Another 898 offspring are
children of cohort members where only one parent was a
study participant; they were recruited because their par-
ents exhibited elevated lipid levels. In addition, 1576 off-
spring cohort participants are spouses of offspring. The
offspring cohort has been followed every 4 years (except
between Exams 1 and 2 with an intervening 8 years) using
protocols similar to those used for study of the original
cohort.
In the mid-1990s about 1800 members of the largest 330
pedigrees were selected for a genome scan that was con-
ducted by the Mammalian Genotyping Service in Marsh-
field, Wisconsin. The expanded pedigrees consist of 4692
subjects, of whom 2885 have participated in the Framing-
ham Heart Study. Among the Framingham participants in
these 330 pedigrees, there are 3041 parent-offspring pairs,
2796 sib pairs, 2107 avuncular pairs, 183 grandparent-
grandchild pairs, and 1595 first-cousin pairs.
For the Genetics Analysis Workshop 13, we provide data
for systolic blood pressure, height, weight, total choles-
terol, fasting HDL cholesterol and triglycerides, blood glu-
cose, and appropriate covariates such as age, sex, smoking,
and alcohol consumption. These data were provided for
Study participants in the 330 pedigrees from the original
and the offspring cohorts. Data were provided for the first
40 years of follow up in the original cohort (Exams 1
through 21) and the first 20 years of follow up in the off-
spring cohort (Exams 1 through 5).
Over the years, careful monitoring of the Framingham
Study sample has led to the identification or validation of
the major CVD risk factors-high blood pressure, high
blood cholesterol, low HDL cholesterol, smoking, obes-
ity, diabetes, and physical inactivity-as well as a great deal
of valuable information on the effects of related factors
such as blood triglyceride levels, age, gender, and psycho-
social factors. Although the Framingham cohorts are pri-
marily White, the importance of the major CVD risk
factors identified in this group have been shown in other
studies to apply almost universally among racial and eth-
nic groups, even though the patterns of distribution may
vary from group to group [2]. In the past 50 years, the
study has produced over 1200 articles in leading medical
journals. The concept of CVD risk factors has become an
integral part of the modern medical curriculum and has
led to the development of effective treatment and preven-
tive strategies in clinical practice.
The Framingham Heart Study continues to make impor-
tant scientific contributions by enhancing its research
capabilities and capitalizing on its inherent resources.
New diagnostic technologies, such as echocardiography
(an ultrasound examination of the heart), carotid artery
ultrasound, and bone densitometry (for monitoring oste-
oporosis), are evaluated and integrated into ongoing pro-
tocols.
While pursuing the Study's established research goals, the
NHLBI and the Framingham investigators are expanding
their research into other areas such as the role of genetic
factors in CVD. One project currently under way is the
establishment of immortalized cell lines from surviving
original cohort participants and members of the offspring
cohort. These cell lines will enable extensive investigation
of the genetic etiology of not only CVD, but also other dis-
eases. Framingham investigators also collaborate with
leading researchers from around the country and through-
out the world on projects in stroke and dementia, oste-
oporosis and arthritis, nutrition, diabetes, eye diseases,
hearing disorders, lung diseases, and genetic patterns of
common diseases.
The unflagging commitment of the research participants
in the NHLBI Framingham Heart Study has made more
than 50 years of research success possible. Further infor-
mation on the Study can be found at http://
www.nhlbi.nih.gov/about/framingham/index.html. The
Study invites researchers around the world to consider
this rare collection of data as a resource that may further
their own research. There are established protocols for
requesting data and/or DNA samples and investigators are
encouraged to pursue research questions using this
resource.
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